Synthetic peptides blocking sars-cov-2 (covid-19), and compositions, methods and uses related thereto

The invention relates to the field of medicine and therapeutically active peptides, more specifically to the design of peptides that antagonise Angiotensin-Converting Enzyme-2 (ACE-2) interaction with the receptor binding spike protein of SARS-CoV-2. Provided is a peptidic compound comprising or consisting of an amino acid sequence selected from the following: IYALLENAEDYNLVN, SRDKHEEHEKENDRGQ, DKFNHEAEDLFYQSSLASWNYNT, IEEQAKTFLDKFQHEVEEIYWQS, QDKHEEDYQMYNKGDKED and IDENARSYIDKFQHDAEEMWYQ, or an amide, an ester or a salt thereof

Oral dosage forms of a therapeutically active acid-labile salt and methods and uses related thereto.

The invention relates to the field of oral drug delivery and more in particular, to oral dosage forms for delivery of a high dose of a therapeutically active acid-labile salt, such as sodium thiosulfate (STS). Provided is a pharmaceutical oral dosage form for controlled delivery of an acid-labile salt, the dosage form comprising a core comprising the acid-labile salt in a polymer matrix comprising a combination of (i) a pH- sensitive hydrophilic methacrylic acid— methyl methacrylate copolymer and (ii) a carbomer, wherein the acid-labile salt makes up at least 50wt% of the core; and wherein the outer surface of the core is provided with an enteric coating layer

Oral dosage forms of a therapeutically active acid-labile salt and methods and uses related thereto.

The invention relates to the field of oral drug delivery and more in particular, to oral dosage forms for delivery of a high dose of a therapeutically active acid-labile salt, such as sodium thiosulfate (STS). Provided is a pharmaceutical oral dosage form for controlled delivery of an acid-labile salt, the dosage form comprising a core comprising the acid-labile salt in a polymer matrix comprising a combination of (i) a pH- sensitive hydrophilic methacrylic acid— methyl methacrylate copolymer and (ii) a carbomer, wherein the acid-labile salt makes up at least 50wt% of the core; and wherein the outer surface of the core is provided with an enteric coating layer

Oral dosage forms of a therapeutically active acid-labile salt and methods and uses related thereto.

The invention relates to the field of oral drug delivery and more in particular, to oral dosage forms for delivery of a high dose of a therapeutically active acid-labile salt, such as sodium thiosulfate (STS). Provided is a pharmaceutical oral dosage form for controlled delivery of an acid-labile salt, the dosage form comprising a core comprising the acid-labile salt in a polymer matrix comprising a combination of (i) a pH- sensitive hydrophilic methacrylic acid— methyl methacrylate copolymer and (ii) a carbomer, wherein the acid-labile salt makes up at least 50wt% of the core; and wherein the outer surface of the core is provided with an enteric coating layer